tiprankstipranks
Trending News
More News >
Xenetic Biosciences (XBIO)
NASDAQ:XBIO

Xenetic Biosciences (XBIO) AI Stock Analysis

Compare
297 Followers

Top Page

XB

Xenetic Biosciences

(NASDAQ:XBIO)

Rating:43Neutral
Price Target:
Xenetic Biosciences is currently facing substantial financial and operational challenges, as evidenced by its negative profitability and cash flow metrics. The technical analysis further supports a cautious outlook, with bearish indicators across key metrics. Valuation remains a concern due to the lack of earnings. However, the company's strong equity position and absence of debt offer some stability as it navigates these challenges.
Positive Factors
Clinical Development
Xenetic entered into a clinical trial services agreement with Israeli-based biotechnology company PeriNess Ltd. to advance efforts for the clinical development of its DNase I based oncology platform and lead candidate XBIO-015.
Financial Performance
Xenetic announced 1Q25 financial results, posting EPS of ($0.59) compared to an estimate of ($0.72).
Preclinical Results
Strong preclinical results show DNase I therapy can inhibit tumor growth and enhance survival in colorectal cancer models.
Negative Factors
Clinical Trial Risks
The potential for value-driving regulatory and clinical milestones for Xenetic is dependent on the success of the DNase-based platform.
Regulatory Challenges
The addition of the DNase-based platform faces the challenge of reaching regulatory and clinical milestones to drive value for Xenetic.

Xenetic Biosciences (XBIO) vs. SPDR S&P 500 ETF (SPY)

Xenetic Biosciences Business Overview & Revenue Model

Company DescriptionXenetic Biosciences, Inc. (XBIO) is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs. The company primarily operates in the field of oncology, leveraging its proprietary technologies to advance its drug development pipeline. Xenetic is known for its platform technologies that enhance the efficacy and safety profiles of biologic drugs, particularly in the treatment of cancer.
How the Company Makes MoneyXenetic Biosciences makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves licensing its technologies to pharmaceutical partners, thereby earning milestone payments and royalties on the sales of drugs developed using its platforms. Xenetic also engages in collaborations and strategic partnerships to co-develop therapies, which may include upfront payments, research funding, and shared revenues from successful products. Additionally, the company may receive government grants and funding to support its research initiatives.

Xenetic Biosciences Financial Statement Overview

Summary
Xenetic Biosciences is facing significant profitability challenges, with negative net profit margins and ongoing operational inefficiencies. While the company maintains a strong equity ratio and zero debt, its negative cash flow and return on equity highlight struggles in generating positive returns for shareholders.
Income Statement
35
Negative
Xenetic Biosciences has shown inconsistent revenue growth, with the latest annual revenue decreasing slightly by 1.6%. The gross profit margin remains strong at 100%, indicating efficient cost management relative to revenue. However, the company faces significant challenges with profitability, as evidenced by a negative net profit margin of -158.4% and consistent EBIT and EBITDA losses, reflecting operational inefficiencies.
Balance Sheet
60
Neutral
The balance sheet shows a strong equity position with an equity ratio of 87%. The company has no debt, which minimizes financial risk and provides stability. However, the return on equity is negative due to ongoing net losses, highlighting challenges in generating shareholder returns.
Cash Flow
40
Negative
Operating cash flow remains negative, indicating ongoing cash consumption in operations. The free cash flow also reflects a negative trend, although there is a slight improvement from the previous year. The cash flow to net income ratios are not favorable due to negative net income, suggesting struggles in translating operational activities into positive cash flows.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
2.58M2.50M2.54M1.71M1.16M436.94K
Gross Profit
1.99M2.50M2.54M1.68M1.13M436.94K
EBIT
-3.88M-4.20M-4.52M-6.72M-5.75M4.55M
EBITDA
-3.88M-4.20M-4.54M-6.72M-5.71M-4.69M
Net Income Common Stockholders
-3.67M-3.96M-4.13M-6.39M-5.54M-10.89M
Balance SheetCash, Cash Equivalents and Short-Term Investments
5.16M6.17M8.98M13.10M18.24M11.53M
Total Assets
5.79M6.90M10.61M14.72M19.82M13.18M
Total Debt
0.000.000.000.0027.04K62.52K
Net Debt
-5.16M-6.17M-8.98M-13.10M-18.22M-11.47M
Total Liabilities
667.93K894.26K809.59K1.07M1.42M963.97K
Stockholders Equity
5.12M6.01M9.80M13.65M18.39M12.22M
Cash FlowFree Cash Flow
-2.66M-2.82M-4.11M-5.15M-4.74M-4.27M
Operating Cash Flow
-2.66M-2.82M-4.11M-4.65M-4.74M-4.27M
Investing Cash Flow
0.000.000.00-500.00K0.000.00
Financing Cash Flow
0.000.000.000.0011.45M5.43M

Xenetic Biosciences Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.00
Price Trends
50DMA
2.88
Positive
100DMA
3.47
Negative
200DMA
3.71
Negative
Market Momentum
MACD
0.05
Negative
RSI
52.71
Neutral
STOCH
43.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Negative. The current price of 3 is above the 20-day moving average (MA) of 2.98, above the 50-day MA of 2.88, and below the 200-day MA of 3.71, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 52.71 is Neutral, neither overbought nor oversold. The STOCH value of 43.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XBIO.

Xenetic Biosciences Risk Analysis

Xenetic Biosciences disclosed 67 risk factors in its most recent earnings report. Xenetic Biosciences reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Xenetic Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$5.14B3.23-45.01%2.85%17.55%-0.69%
45
Neutral
$3.73M-100.01%6.87%
43
Neutral
$4.63M-53.16%-1.56%5.01%
41
Neutral
$4.57M-423.79%19.75%95.65%
31
Underperform
$4.00M-2639.52%19.58%
29
Underperform
$4.08M-748.05%-100.00%76.55%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XBIO
Xenetic Biosciences
3.00
-0.82
-21.47%
KZIA
Kazia Therapeutics
3.58
-10.16
-73.94%
TOVX
Theriva Biologics
0.46
-6.32
-93.22%
JAGX
Jaguar Animal Health
4.49
-96.26
-95.54%
OGEN
Oragenics
0.19
-1.93
-91.04%

Xenetic Biosciences Corporate Events

Business Operations and Strategy
Xenetic Biosciences Expands Collaboration for Cancer Treatment
Positive
Nov 7, 2024

Xenetic Biosciences has extended its collaboration with The Scripps Research Institute to further develop its DNase oncology platform. This initiative aims to enhance cancer treatment efficacy by targeting neutrophil extracellular traps, which promote cancer progression. The partnership focuses on combining DNase with CAR T-cell therapies, showing promise in preclinical studies for reducing tumor burden and improving therapeutic responses, with plans to advance towards clinical development for pancreatic and other solid tumors.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.